BCAB
Bioatla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
时间：2024-12-20 22:00:01 市场： 美股 综合
Context Therapeutics Inc - Anticipates Ind Filing for Ba3362 in Mid-2026
时间：2024-09-23 19:30:15 市场： 综合 美股
Context Therapeutics Inc - Bioatla to Receive $15 Mln Upfront, up to $118.5 Mln in Milestones
时间：2024-09-23 19:30:15 市场： 美股 综合
Bioatla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize Ba3362, a Nectin-4 X Cd3 T Cell Engaging Antibody
时间：2024-09-23 19:30:00 市场： 美股 综合